Diabetes Mellitus Clinical Trial
Official title:
Melatonin Supports Non Surgical Periodontal Treatment in Patients With Type 2 Diabetes and Periodontitis
Verified date | May 2023 |
Source | Recep Tayyip Erdogan University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Background and aim: Hyperinflammatory host response associated with diabetes mellitus significantly provokes periodontal tissue destruction. In this context, supporting the standard treatment of periodontitis in diabetics with host modulation agents is a current field of study. This clinical study aims to investigate the clinical efficacy of melatonin supplementation in non-surgical periodontal treatment in patients with Type 2 DM and periodontitis and its biological basis (clinical effectiveness) based on some basic markers. Material and method: In this randomized controlled and double-blind study, 27 of 55 patients with diabetic periodontitis underwent full mouth scaling and root planning (fmSRP) alone and 28 of them were administered melatonin (6 mg daily, for 30 days) in addition to fmSRP. The possible therapeutic contribution of melatonin was evaluated clinically and biochemically [gingival crevicular fluid (GCF) RANKL, OPG and MMP-8 and serum IL-1β levels] at 3 and 6 months.
Status | Completed |
Enrollment | 55 |
Est. completion date | June 18, 2022 |
Est. primary completion date | January 18, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 31 Years to 65 Years |
Eligibility | Inclusion Criteria: - According to the WHO, in individuals in the young age category (18-65 years) - Periodontitis diagnosed patients, "stage 3/4 periodontitis" was determined according to the current periodontal disease and condition classification as the diagnostic criterion for periodontitis - Diabetic patients, our diagnostic criteria for Type 2 DM was fasting plasma glucose level greater than 126 mg/dl and glycosylated hemoglobin level (HbA1c) greater than 6.5%. Exclusion Criteria: - Smoke, use antibiotics, anti-inflammatory and antioxidant drugs in the last 6 months - Work night shifts - Pregnancy and lactation - Cancer and autoimmune diseases - Kidney disease - Periodontal treatment in the last 6 months - Obese patients (In Europe, obesity is defined as a body-mass index of more than 30 kg/m2 and a waist circumference of more than 88 cm in women and 102 cm in men) |
Country | Name | City | State |
---|---|---|---|
Turkey | Yagmur Sarac Gul | Rize |
Lead Sponsor | Collaborator |
---|---|
Yagmur Saraç Gül |
Turkey,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Clinical Findings: Plaque index score(PI) | According to the tooth Plaque index, each tooth surface was divided into 4 separate regions and the plaque intensity for each region is scored as:
0 = No plaque in the gingival area. = A film of plaque adhering to the free gingival margin and adjacent area of the tooth. The plaque may only be recognized by running a probe across the tooth surface. = Moderate accumulation of soft deposits within the gingival pocket, on the gingival margin and/or adjacent tooth surface, which can be seen by the naked eye. = Abundance of soft matter within the gingival pocket and/or on the gingival margin and adjacent tooth surface. Finally, scores are collected and calculate the arithmetic mean for the mouth score. |
Change from baseline(T0) to 3rd month(T1) and 6th month(T2) | |
Primary | Clinical Findings: Gingival index score (GI) | The criteria are entirely confined to qualitative changes in the gingival soft tissue.Periodontal probe was used and gently inserted the sulcus. Each tooth surface was divided into 4 separate regions and the gingival bleeding activity for each region is scored as:
0 = Normal gingiva = Mild inflammation -slight change in color, slight oedema. No bleeding on probing = Moderate inflammation-redness, oedema and glazing. Bleeding on probing =Severe inflammation -marked redness and oedema. Ulceration. Tendency to spontaneous bleeding. Finally, scores are collected and calculate the arithmetic mean for the mouth score. |
Change from baseline(T0) to 3rd month(T1) and 6th month(T2) | |
Primary | Clinical Findings: Bleeding on probing(BOP) | Each tooth surface was divided into 4 separate regions and gently probed by using periodontal probe.There is a bleeding as a positive score, and there is no bleeding as a negative score. The BOP is considered positive if bleeding occurred between 30 seconds after probing. Whole the probed area and positive score area ratio were calculated and BOP(%)score was found. | Change from baseline(T0) to 3rd month(T1) and 6th month(T2) | |
Primary | Clinical Findings:Probing pocket depth (PPD) | Probing pocket depth (PPD) measured with a periodontal probe on 6 different points around each tooth. PPD is known as distance between gingival margin and the base of the pocket/sulcus. By using periodontal probe(Williams periodontal probe) 6 different points are measured. Each scores of surfaces are collected and averaged for the mouth score for PPD. | Change from baseline(T0) to 3rd month (T1) and 6th month (T2) | |
Primary | Clinical Findings: Clinical Attachment Level (CAL) | By using periodontal probe(Williams periodontal probe) 6 different points are measured.CAL, distance from the bottom of the pocket to the cemento-enamel junction of tooth. If there is gingival recession, recession depth is also added the CAL. By using periodontal probe(Williams periodontal probe) 6 different points are measured. Each scores of surfaces are collected and averaged for the mouth score for CAL. | Change from baseline(T0) to 3rd month(T1) and 6th month(T2) | |
Primary | Biochemical Findings: RANKL (pg/ml) | RANKL (pg/ml) were measured samples from gingival crevicular fluid by using commercial ELISA kits according to the instructions of the kit manufacturer | Change from baseline(T0) to 3rd month(T1) and 6th month(T2) | |
Primary | Biochemical Findings: OPG (pg/ml) | OPG (pg/ml) were measured samples from gingival crevicular fluid by using commercial ELISA kits according to the instructions of the kit manufacturer | Change from baseline(T0) to 3rd month(T1) and 6th month(T2) | |
Primary | Biochemical Findings: MMP-8(ng/ml) | MMP-8(ng/ml) were measured samples from gingival crevicular fluid by using commercial ELISA kits according to the instructions of the kit manufacturer | Change from baseline(T0) to 3rd month(T1) and 6th month(T2) | |
Primary | Biochemical Findings: IL-beta(pg/ml) | IL-beta(pg/ml) were measured samples from serum by using commercial ELISA kits according to the instructions of the kit manufacturer | Change from baseline(T0) to 3rd month(T1) and 6th month(T2) | |
Primary | Biochemical Findings: RANKL/OPG | RANKL/OPG, numeric ratio that can be indicated as only numeric value(no need some kind of units) | Change from baseline(T0) to 3rd month(T1) and 6th month(T2) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03743779 -
Mastering Diabetes Pilot Study
|
||
Completed |
NCT03786978 -
Pharmaceutical Care in the Reduction of Readmission Rates in Diabetes Melitus
|
N/A | |
Completed |
NCT01804803 -
DIgital Assisted MONitoring for DiabeteS - I
|
N/A | |
Completed |
NCT05039970 -
A Real-World Study of a Mobile Device-based Serious Health Game on Session Attendance in the National Diabetes Prevention Program
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Completed |
NCT04068272 -
Safety of Bosentan in Type II Diabetic Patients
|
Phase 1 | |
Completed |
NCT03243383 -
Readmission Prevention Pilot Trial in Diabetes Patients
|
N/A | |
Completed |
NCT03730480 -
User Performance of the CONTOUR NEXT and CONTOUR TV3 Blood Glucose Monitoring System (BGMS)
|
N/A | |
Recruiting |
NCT02690467 -
Efficacy, Safety and Acceptability of the New Pen Needle 34gx3,5mm.
|
N/A | |
Completed |
NCT02229383 -
Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus
|
Phase 3 | |
Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
Completed |
NCT06181721 -
Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Patients With Type 1 and Type 2 Diabetes
|
N/A | |
Recruiting |
NCT04489043 -
Exercise, Prediabetes and Diabetes After Renal Transplantation.
|
N/A | |
Withdrawn |
NCT03319784 -
Analysis for NSAID VS Corticosteroid Shoulder Injection in Diabetic Patients
|
Phase 4 | |
Completed |
NCT03542084 -
Endocrinology Auto-Triggered e-Consults
|
N/A | |
Completed |
NCT02229396 -
Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo
|
Phase 3 | |
Recruiting |
NCT05544266 -
Rare and Atypical Diabetes Network
|
||
Completed |
NCT01892319 -
An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry
|
||
Completed |
NCT05031000 -
Blood Glucose Monitoring Systems: Discounter Versus Brand
|
N/A | |
Recruiting |
NCT04039763 -
RT-CGM in Young Adults at Risk of DKA
|
N/A |